A Study On Prescriptions Contributing To The Risk Of High Anticholinergic Burden In Adults With Intellectual Disabilities: Retrospective Record Linkage Study DOI Creative Commons
Laura Ward, Sally‐Ann Cooper, Angela Henderson

и другие.

Research Square (Research Square), Год журнала: 2022, Номер unknown

Опубликована: Март 11, 2022

Abstract Background : People with intellectual disabilities face a disproportionate risk of experiencing high anticholinergic burden, and its negative sequalae, at younger ages than the general population. Our aim was to determine source that burden from prescribed medication. Methods Retrospective matched observational study using record linkage. Adults (n=4,305), without (n=12,915), by age-, sex- neighbourhood deprivation. The main outcome measure prescription long-term (approximately 9 months use) medications overall, drug class, individual drugs, polypharmacy. Results 38.4% 23.6% adults with, without, were properties. Of those on such most likely be central nervous system (62.6%), gastrointestinal (46.7%), cardiovascular (28.4%) medications. They more system, gynaecological/urinary tract, musculoskeletal, respiratory medications, less cardiovascular, infection, endocrine their comparators. Regardless age, sex, or deprivation, had greater odds being antipsychotics (OR=5.37 [4.40-6.57], p<0.001), antiepileptics (OR=2.57 [2.22-2.99], anxiolytics/hypnotics (OR=1.28 [1.06-1.56], p=0.012). exposed overall polypharmacy (61.3% (n=1,013), 54.7% (n=1,668) respectively, OR=1.48 [1.33-1.66], psychotropic (33.7% (n=558), 14.3% (n=435) OR=2.79 [2.41-3.23], p<0.001). Conclusions are having very through several classes which may different prescribers. Clinicians need cognisant this issue, potential adverse consequences. These findings highlight for regular medication reviews reduce inappropriate prescribing effects.

Язык: Английский

Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art DOI Creative Commons
Philip D. Harvey, Marta Bosia, Roberto Cavallaro

и другие.

Schizophrenia Research Cognition, Год журнала: 2022, Номер 29, С. 100249 - 100249

Опубликована: Март 22, 2022

Cognitive impairment in schizophrenia represents one of the main obstacles to clinical and functional recovery. This expert group paper brings together experts treatment discuss scientific progress domain cognitive address impairments their consequences most effective way. We report on onset course deficits, linking them alterations brain function structure discussing role predicting transition psychosis people at risk. then assessment tools with reference functioning social cognition, examining subjective measures addressing new methods for measuring outcomes including technology based approaches. Finally, we briefly review options focusing remediation programs, highlighting effects activity conclude potential benefit individualized integrated interventions combing other

Язык: Английский

Процитировано

95
Beauty of the beast: anticholinergic tropane alkaloids in therapeutics DOI Creative Commons
Kyu-Hwan Shim, Min Ju Kang, Niti Sharma

и другие.

Natural Products and Bioprospecting, Год журнала: 2022, Номер 12(1)

Опубликована: Сен. 16, 2022

Abstract Tropane alkaloids (TAs) are among the most valued chemical compounds known since pre-historic times. Poisonous plants from Solanaceae family ( Hyoscyamus niger, Datura, Atropa belladonna , Scopolia lurida, Mandragora officinarum, Duboisia ) and Erythroxylaceae Erythroxylum coca rich sources of tropane alkaloids. These possess anticholinergic properties as they could block neurotransmitter acetylcholine action in central peripheral nervous system by binding at either muscarinic and/or nicotinic receptors. Hence, great clinical importance used antiemetics, anesthetics, antispasmodics, bronchodilator mydriatics. They also serve lead to generate more effective drugs. Due important pharmacological listed WHO list essential medicines available market with FDA approval. However, being action, TA medication under suspicion causing dementia cognitive decline like other medications interestingly which is incorrect. There published reviews on chemistry, biosynthesis, pharmacology, safety concerns, biotechnological aspects TAs but detailed information mechanism approval burden lacking. Hence present review tries fill this lacuna critically summarizing discussing above mentioned aspects. Graphical

Язык: Английский

Процитировано

24
The Assessment of the Relationship Between Anticholinergic Burden and Short-Term Blood Pressure Variability DOI

Furkan KÖŞKER,

Reşit Emre ALPARĞAN,

Muhammed Ali COŞKUNER

и другие.

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Апрель 15, 2025

Abstract Background: This study aimed to investigate the relationship between short-term blood pressure variability (BPV) and anticholinergic burden (ACB) in adults with hypertension. Methods:This included 238 hypertensive patients aged 50 older who underwent ambulatory monitoring. The medications used by were recorded, ACB of each medication was calculated using Scale. BPV assessed based on 24-hour measurements three methods: standard deviation (SD), coefficient variation (SD-CoV), weighted (wSD), evaluations conducted for both day-time night-time periods. Results: A total 139 (58.4%) had no score, 64 (26.9%) an score 1, 35 (14.7%) 2 or higher. scores significantly higher among heart disease. Both tended increase age. However, statistically significant found mean pressure, nocturnal dips, any parameters BPV. Conclusion: No association To best our knowledge, this is first relationship, which may inspire further research.

Язык: Английский

Процитировано

0
Association of systemic anticholinergic medication use and accelerated decrease in lung function in older adults DOI Creative Commons
Markus Svensson, Sölve Elmståhl, Johan Berglund

и другие.

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Фев. 22, 2024

Abstract Older adults are frequently exposed to medicines with systemic anticholinergic properties, which linked increased risk of negative health outcomes. The association between anticholinergics and lung function has not been reported. aim this study was investigate if exposure influences in older adults. Participants the southernmost centres Swedish National on Aging Care (SNAC) were followed from 2001 2021. In total, 2936 subjects (2253 Good Skåne 683 SNAC-B) included. An extensive medical examination including spirometry assessments performed during visits. burden described using cognitive scale. effect new use annual change forced expiratory volume (FEV1s) estimated mixed models. During follow-up, 802 (27.3%) participants at least one medicine. On average, FEV1s without decreased 37.2 ml/year (95% CI [33.8; 40.6]) while low high lose 47.2 [42.4; 52.0]) 43.7 [25.4; 62.0]). A novel properties accelerated decrease found. is comparable that observed smokers. Studies needed further explore potential side anticholinergics.

Язык: Английский

Процитировано

2
Development of the Swedish anticholinergic burden scale (Swe-ABS) DOI Creative Commons
Tanja Rube,

Astrid Ecorcheville,

Elisabet Londos

и другие.

BMC Geriatrics, Год журнала: 2023, Номер 23(1)

Опубликована: Авг. 25, 2023

Abstract Background Drugs with anticholinergic properties are associated cognitive adverse effects, especially in patients vulnerable to central muscarinic antagonism. A variety of drugs show weak, moderate or strong effects. Therefore, the cumulative burden should be considered impairment. This study aimed develop a Swedish Anticholinergic Burden Scale (Swe-ABS) used health care and research. Methods systematic literature review was conducted PubMed Ovid Embase identify previously published tools quantifying drug (i.e., exposure). grading scores (0–3, no high activity) were extracted from identified lists. Enteral parenteral authorized Sweden included. conflicting existing lists assessed by an expert group. Two that not also added evaluation process. Results The search following nine scales: Activity Scale, Classification, updated Cognitive scale, Drug Load Risk Clinician-rated German Korean Scale. list significant effects provided National Board Health Welfare included suggested Swe-ABS consists 104 scored as having hundred fifty-six listed based on previous scales. In total, 62 Conclusions is simplified method quantify easy use clinical practice. Publication this scale might make clinicians more aware patients’ total burden. Further research needed validate evaluate exposure versus clinically outcomes.

Язык: Английский

Процитировано

5
Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment and self-reported side effects in the euthymic phase of bipolar disorders: Results from the FACE-BD cohort DOI Creative Commons

Neus Barrantes Vidal,

Éric Brunet,

S. Frileux

и другие.

European Neuropsychopharmacology, Год журнала: 2023, Номер 77, С. 67 - 79

Опубликована: Сен. 21, 2023

Язык: Английский

Процитировано

5
A study on prescriptions contributing to the risk of high anticholinergic burden in adults with intellectual disabilities: retrospective record linkage study DOI Creative Commons

McKernan Laura Ward,

Sally‐Ann Cooper, Angela Henderson

и другие.

Annals of General Psychiatry, Год журнала: 2022, Номер 21(1)

Опубликована: Окт. 29, 2022

People with intellectual disabilities may face a disproportionate risk of experiencing high anticholinergic burden, and its negative sequalae, from range medications, at younger ages than the general population, but there has been little previous study. Our aim was to determine source burden prescribed medication.Retrospective matched observational study using record linkage. Adults (n = 4,305), without 12,915), by age-, sex- neighbourhood deprivation. The main outcome measure prescription long-term (approximately 12 months use) medications overall (classified according Anticholinergic Risk Scale [ARS]), drug class, individual drugs, polypharmacy.Adults n 1,654 (38.4%), 3,047 (23.6%), were effects. Of those on such adults most likely be central nervous system (62.6%), gastrointestinal (46.7%), cardiovascular (28.4%) medications. They more system, gynaecological/urinary tract, musculoskeletal, respiratory less cardiovascular, infection, endocrine their comparators. Regardless age, sex, or deprivation, had greater odds being antipsychotics (OR 5.37 [4.40-6.57], p < 0.001), antiepileptics 2.57 [2.22-2.99], anxiolytics/hypnotics 1.28 [1.06-1.56], 0.012). Compared exposed polypharmacy 1.48 [1.33-1.66], psychotropic 2.79 [2.41-3.23], 0.001).Adults are having very through several classes which different prescribers. There is need for evidence-based recommendations specifically about people multiple physical mental ill-health conditions optimise medication use, reduce inappropriate prescribing adverse

Язык: Английский

Процитировано

6
Anticholinergics and falls in older adults DOI

Xiang Jiang Xu,

Maw Pin Tan

Expert Review of Clinical Pharmacology, Год журнала: 2022, Номер 15(3), С. 285 - 294

Опубликована: Март 4, 2022

The use of medications with anticholinergic (ACh) properties is associated numerous adverse effects especially in older adults. Emerging evidence suggests the presence long-term ACh use.Our article presents an overview and falls individuals including examination emerging on cumulative exposure short-term risk. databases CINAHL, MEDLINE, EMBASE, Web Science were searched for articles published from January 2002 to December 2021.Anticholinergic side include muscle weakness, blurred vision, mental confusion which are likely lead increased Many commonly used such as beta-blockers, calcium-channel blockers, antihistamines now known have mild properties. With polypharmacy considered unavoidable patients, multiple drugs may also relationship between be irreversible extend beyond period drug use, due cognitive physical deconditioning following initial drugs. Future studies accurate quantification measurement actual outcomes urgently required.

Язык: Английский

Процитировано

5
Health-related quality of life and use of medication with anticholinergic activity in patients with multiple myeloma DOI
Mariana Sampaio Rodrigues de Lima, Cristiane Aparecida Menezes de Pádua, Paula Lana de Miranda Drummond

и другие.

Supportive Care in Cancer, Год журнала: 2023, Номер 31(7)

Опубликована: Июнь 6, 2023

Язык: Английский

Процитировано

2
Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial DOI Creative Commons
Diane K. Newman, Elizabeth Thomas,

Heather Greene

и другие.

Urogynecology, Год журнала: 2022, Номер 29(1), С. 48 - 57

Опубликована: Окт. 21, 2022

The international phase 3 EMPOWUR trial demonstrated efficacy and safety of vibegron, a newer β -adrenergic receptor agonist, in adults with overactive bladder (OAB). Women are disproportionately affected by OAB, especially those bothersome symptoms, such as urge urinary incontinence (UUI).

Язык: Английский

Процитировано

3